PriceSensitive

Optimi Health (CSE:OPTI) approved to supply psilocybin via a Health Canada program

Psychedelics
CSE:OPTI
16 February 2022 12:00 (EDT)

Optimi Health’s (OPTI) subsidiary has been approved under the Special Access Program (SAP) to supply psilocybin for medical purposes.

Optimi is focused on bringing change to those suffering from debilitating palliative and non-palliative mental health trauma.

The SAP allows medical practitioners to request access to use psilocybin on a case-by-case emergency basis.

With Optimi’s license approved by Health Canada earlier this month, it received requests for supply agreements from potential partners interested in the new EU-GMP compliant facility in Princeton, B.C.

Optimi will have a grand opening for its new facility this May and will be building awareness about the benefits of SAP to physicians qualified to recommend the program to patients.

SAP is already displaying a positive impact on patients in need. The program will provide a way for the company to develop and supply the demand for natural psilocybin.

Bill Ciprick, CEO of Optimi, commented

“We will leave no stone unturned in our effort to provide the safest and most efficacious natural psilocybin product in the world, because frankly we need to get this right for those depending on us for support and healing.”

Practitioners were prohibited from requesting access to psilocybin and MDMA for individual psychedelic-assisted psychotherapy until recent amendment changes.

The amendments have the potential to positively affect the lives of people experiencing serious mental health conditions and end-of-life distress when other therapies have failed, are unsuitable or are unavailable in Canada.

Optimi Health Corp.(OPTI) is up 6.67 per cent trading at $0.40 per share as of11:34 a.m. EST.

Related News